Gene · 6118
RPA2: replication protein A2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPA2: replication protein A2. Genes, record 6118. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6118
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P15927 | Replication protein A 32 kDa subunit | 270 | 14 | Ensembl, GeneID, HGNC |
Source UniProt
Patents56
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4791890 A2 | 2026-08-19 | 119 | P15927 | Espacenet |
| JP 2026009871 A | 2026-01-21 | 141 | P15927 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61397 | P15927 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9398 | P15927 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9398 | P15927 | Espacenet |
| US 12281338 B2 | 2025-04-22 | 67 | P15927 | Espacenet |
| EP 4464338 A2 | 2024-11-20 | 319 | P15927 | Espacenet |
| KR 1020240116572 A | 2024-07-29 | 141 | P15927 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 201 | P15927 | Espacenet |
| US 11932884 B2 | 2024-03-19 | 369 | P15927 | Espacenet |
1 to 10 of 56
See all 56 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,906
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPA2 papers | Newest fiscal year |
|---|---|---|---|
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 38 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 30 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 20 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 13 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 11 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 11 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 10 | 2025 |
| R01HL052725 | Molecular Pathogenesis of Fanconi Anemia | 10 | 2025 |
| T32CA009582 | Biochemical and Chemical Training for Cancer Research | 10 | 2025 |
| ZIABC006150 | DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs | 10 | 2025 |
1 to 10 of 1,906Source NIH's project files
See all 1,906 nih grantsPapers2,490
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer. | Biomedicines | 2026 | 42792682 | PubTator, text mining | PubMed |
| Nanoparticle Co-delivery of Microtubule Inhibitors and Cisplatin Overcomes DNA Repair-Mediated Resistance in Head and Neck Cancer. | Mol Cancer Ther | 2026 | 42777141 | PubTator, text mining | PubMed |
| The KEAP1-NFE2L2/NRF2 Axis in Non-Small Cell Lung Cancer Radioresistance: Redox Homeostasis and Emerging DNA Damage Response Mechanisms. | Cancer Manag Res | 2026 | 42708106 | PubTator, text mining | PubMed |
| Corrigendum to "CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through the CSDE1-eIF3a regulatory complex" [Drug Resist. Updat. 81 (2025) 101249]. | Drug Resist Updat | 2026 | 42632763 | PubTator, text mining | PubMed |
| The tumor suppressor menin is a key scaffold mediator for homologous recombination repair. | Nucleic Acids Res | 2026 | 42578372 | PubTator, text mining | PubMed |
| Fission yeast RPA-TERT-Tpz1TPP1 complex promotes telomere extension and suppresses telomere recombination. | bioRxiv | 2026 | 42539071 | PubTator, text mining | PubMed |
| EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. | Cell Death Dis | 2026 | 42336814 | PubTator, text mining | PubMed |
| TEAD1 condensates are transcriptionally inactive storage sites on the pericentromeric heterochromatin in cancer cells. | Nat Cell Biol | 2026 | 42277434 | PubTator, text mining | PubMed |
| A RHNO1-ATR/Chk1 positive feedback loop sustains the DNA replication stress response. | bioRxiv | 2026 | 42239230 | PubTator, text mining | PubMed |
| Combination of CHK1 and CHK2 inhibitors exerts synergistic antitumor effects against neuroblastoma cells. | Pediatr Res | 2026 | 42230907 | PubTator, text mining | PubMed |
1 to 10 of 2,490
See all 2,490 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6118
GET https://conductscience.org/api/genes/v1/6118/patents?page=2